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822-5 Impact of Radiation Dose on Outcomes in Diabetic 
Patients: Results From the SCRIPPS IV Trial
Paul S. Teirstein, Jeffrey Moses, Martin Leon, Michael Collins, Roxanna Mehran, Eve 
Montang, Manuela Neogota, Huan Giap, Ray Lin, Shirish Jani, Stephen Balter, Jack 
Dalton, Roberto Lipsztein, Matthew J. Price, Prabhakar Tripuraneni, ScrippsClinic 
Research Foundation, La Jolla, CA, Lennox Hill Hospital, New York, NY
Background: The Scripps IV trial invesitagated the safety and efficacy of 14 Gy vs 17 Gy
of gamma intracoronary radiation for the treatment of instent restenosis (ISR). Patients
(pts) with diabetes mellitus (DM) are at particularly high risk for developing recurrent ISR
and may benefit from the higher dosing regimen.
Methods: 358 patients with native or vein graft ISR < 80 mm in length and diameter
between 2.75 and 4 mm were randomized in a double-blind fashion to 14 or 17 Gy at
2mm from the radiation source. Angiography was obtained at 8 months.
Results: Baseline characteristics were equivalent between the 14 Gy and 17 Gy groups
for the DM and non-DM pts, except more males in the DM group received 17 Gy. Mean
lesion length was 22mm and mean vessel diameter was 0.75mm. At 8 months, DM pts
who received 17 Gy had a 57% reduction in MACE (death, MI, or target lesion revascu-
larization, p=0.003), 63% reduction in target lesion revascularization (TLR) (p<0.002),
and a 61% reduction in target vessel revascularzation (TVR) (p<0.001) compared to DM
pts receiving 14 Gy. In contrast, higher dosing did not significantly impact MACE in the
non-DM pts (22.4% vs 16.3%, p=ns). There were no differences in stent thrombosis
between treatment groups in DM or non-DM pts.
Conclusions: In diabetics, a dosing regimen of 17 Gy, instead of the recomended 14 Gy,
of gamma radiation at 2 mm from the source is safe and results in significantly less
MACE, TLR, and TVR at 8 months. Higher dosing of gamma radiation should be consid-
ered when treating diabetic pts.
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822-6 Restenosis After Sirolimus-Eluting Stent Implantation: 
Long-Term Evaluation Following Repeat Percutaneous 
Intervention
Pedro A. Lemos, Chourmouzios A. Arampatzis, Angela Hoye, Joost Daemen, Francesco 
Saia, Andrew T L Ong, Georgios Sianos, Jiro Aoki, Pieter C. Smits, Willem J. van der 
Giessen, Pim de Feyter, Eugenne McFadden, Sjoerd H. Hofma, Ron T. van Domburg, 
Patrick W. Serruys, Erasmus University Medical Center, Rotterdam, The Netherlands
Background: Restenosis after sirolimus-eluting stent (SES) implantation has been
shown to occur in a small but sizeable proportion of cases. Currently, the best manage-
ment of patients with post-SES restenosis remains undefined.
Study Population: From April 2002, drug-eluting stent implantation has been adopted as
the default strategy in our institution, without clinical or anatomical restrictions. During 6
months enrollment, a total of 631 patients received at least one SES. From these, 22
consecutive patients have undergone subsequent repeat percutaneous intervention to
treat post-SES restenosis. The long-term outcomes after the re-treatment are reported.
Results: Patients with post-SES restenosis treated with repeat percutaneous interven-
tion were frequently diabetics (46%). Re-treatment was performed after a median time of
204 days from the index procedure. Most patients were re-treated with implantation of
another drug-eluting stent at the restenotic site: new SES implantation in 10 patients
(46%), and paclitaxel-eluting stent implantation (46%). The remaining 2 patients were
treated with plain balloon dilatation and bare stent implantation respectively. After a
median follow-up of 131 days, the incidence of death, myocardial infarction, or re-inter-
vention was zero. One-year follow-up will be available at the presentation.Conclusions:
Percutaneous re-treatment of post-SES restenosis utilizing repeat drug-eluting stent
implantation as the strategy of choice appears to be safe and associated with very low
incidence of recurrence at medium-term follow-up.
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830-1 Elimination of Soluble Vasoactive Factors by the 
PercuSurge GuardWire Distal Protection Device During 
Percutaneous Coronary Intervention of Saphenous Vein 
Graft
Joseph Salloum, Bhagat Reddy, Douglas E. Vaughan, David X. Zhao, Vanderbilt 
University Medical Center, Nashville, TN
Background: Embolization, vasoconstriction, and in situ thrombosis are potential mech-
anisms of no-reflow during SVG PCI. While most distal protection devices trap debris,
only distal occlusion and aspiration systems such as PercuSurge Guardwire (GW) elimi-
nate soluble factors that can lead to vasoconstriction and in situ thrombosis. Methods:
We tested the hypothesis that soluble vasoactive factors were released during PCI and
removed by GW in 35 consecutive patients underwent SVG PCI using GW. Blood was
taken prior to PCI for baseline measurement of vasoconstrictors: endothelin (ET), seroto-
nin (5-HT), and components of coagulation: tissue factor (TF), plasminogen activator
inhibitor 1 (PAI-1), prothrombin fragment 1+2 (F1+2), and thrombin-antithrombin complex
(TAT). After stenting and before deflating the distal protection balloon, two aspiration runs
were performed with the export catheter and sent for analysis. Results: Levels of vaso-
active factors were substantially higher in the first post-intervention aspirate as compared
to baseline: ET (300% increase, p=0.001), 5-HT (970%, p=0.031), TF (450%, p=0.005),
F1+2 (95%, p=0.04), and TAT (76%, p=0.05). Levels were significantly lower in the sec-
ond aspirate, indicating clearing of these vasoactive factors. Conclusions: Vasoactive
factors are released during SVG PCI. GW effectively removes debris and soluble factors,
which may translate clinically in a more effective distal protection as compared to filter
devices. 
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830-2 Platelet Glycoprotein IIb/IIIa Receptor Inhibition as 
Adjunctive Treatment During Saphenous Vein Graft 
Stenting: Differential Effects After Randomization to 
Occlusion or Filter-Based Embolic Protection
Michael Jonas, Gregg W. Stone, James Hermiller, Robert Feldman, Patrick Hall, Robert 
Haber, Zaki Masud, Patrick Cambier, Ron P. Caputo, Mark Turco, Richard Kovach, Bruce 
Brodie, Howard C. Hermann, David Cox, Roxana Mehran, Campbell Rogers, Brigham 
and Women's Hospital, Boston, MA, Cardiovascular Research Foundation, New York, NY
Background: Embolic protection devices (EPD) reduce complications during saphenous
vein graft (SVG) PCI. However, periprocedural adverse events occur in >10% of patients.
IIb/IIIa inhibitors (IIb/IIIa) have not been proven effective during SVG PCI, although
adjunctive use with certain EPD’s may improve outcomes.
Methods: In the prospective, multicenter FIRE trial, 651 pts undergoing SVG stenting
were randomized to either the FilterWire EX or the balloon occlusion/aspiration Guard-
Wire EPD. IIb/IIIa use was at the discretion of the investigator, but randomization was
stratified by intended use. Data regarding IIb/IIIa treatment was available in 646 pts.
Results: In FIRE, IIb/IIIa were used in 345 (51.5%) FilterWire EX and 301 (53.3%)
GuardWire pts (p=0.65). Patients preselected for IIb/IIIa use had higher baseline risk:
more angina/recent MI (93.9% vs 89.0% p=0.03), lower rate of TIMI 3 flow (77.3% vs
87.1% p=0.001), tighter diameter stenosis (68.6 vs 64.7% p=0.002), and higher SVG
degeneration score. They also had a higher incidence of 30d MACE (12.8% vs 8.0%
p=0.05).
Although overall success rates and 30d outcomes were similar with both EPD’s, marked
differences were noted in IIb/IIIa effect between the FilterWire and GuardWire. As
opposed to the GuardWire population (MACE with IIbIIIa 15.5%, without IIbIIIa 6.3%
Diabetes 14 
Gy
(n=5
0)
17 
Gy
(n=6
4)
p 
value
No Diabetes 14 Gy
(n=11
6)
17 
Gy
(n=9
8)
p 
value
MACE (Death/MI/
TLR)
44.0
%
18.8
%
0.003 MACE (Death/MI/
TLR)
22.4
%
16.3
%
NS
Death 2.0% 4.7% NS Death 0.9% 1.0% NS
TLR 42.0
%
15.6
%
<0.00
2
TLR 20.7
%
15.3
%
NS
TVR 48.0
%
18.8
%
<0.00
1
TVR 26.7
%
23.5
%
NS
MI 2.0% 3.1% NS MI 0.9 1.0% NS
Acute Stent 
Thrombosis
0% 0% NS Acute Stent 
Thrombosis
0% 0%
Late Stent 
Thrombosis
0% 3.1% NS Late Stent 
Thrombosis
1.7% 0%
